Randa TAO, Jamie LECLERC, Kübra YILDIZ, Seong-hoon PARK, Barbara JUNG, David GIUS, Özkan ÖZDEN

Changes in gene expression in SIRT3 knockout liver cells

The sirtuin (SIRT) gene family is reported to regulate critical intracellular processes from aging to cellular metabolism and repair. SIRT3 knockout (SIRT3-/-) mice develop receptor positive mammary tumors starting at 13 months and SIRT3 expression is decreased in human breast cancer samples as well as several other diseases. It is established that carcinogenesis results from the accumulation of multiple aberrant genetic events including the activation of oncogenes and inactivation of tumor-suppressor genes. To determine the potential early genomic events that may play a role in the tumor-permissive phenotype observed in SIRT3-/- cells, we compared gene expression profile in SIRT3-/- and wild-type (SIRT3+/+) mouse livers. Differences between the expression profiles of genes important in the p53 and apoptosis pathway and signal transduction pathways, as well as genes involved with insulin and cholesterol metabolism, were determined. These results demonstrate that the expression of several oncogenes including Cdkn1, Myc, and Nos2 are increased. In contrast, several genes shown to be downregulated in human breast cancer including Btg2, Egr-1, Fos, Jun, Gadd4, and Wnt1 had decreased expression. The current work demonstrates that the loss of function of SIRT3 results in a cellular environment permissive for carcinogenesis and is characterized by altered metabolism.

Anahtar Kelimeler:

SIRT3, mitochondria, gene expression, cancer, metabolism, liver

Changes in gene expression in SIRT3 knockout liver cells

Keywords:

SIRT3, mitochondria, gene expression, cancer, metabolism, liver,

PDF

___

Ahn BH, Kim HS, Song SW, Lee IH, Liu J, Vassilopoulos A, Deng CX, Finkel T (2008). A role for the mitochondrial deacetylase Sirt3 in regulating energy homeostasis. P Natl Acad Sci USA 105: 14447–14452.
Armengol C, Bartolí R, Sanjurjo L, Serra I, Amézaga N, Sala M, Sarrias MR (2013). Role of scavenger receptors in the pathophysiology of chronic liver diseases. Crit Rev Immunol 33: 57–96.
Behrens A, Sibilia M, David JP, Mohle-Steinlein U, Tronche F, Schutz G, Wagner EF (2002). Impaired postnatal hepatocyte proliferation and liver regeneration in mice lacking c-jun in the liver. EMBO J 21: 1782–1790.
Ben Lagha N, Seurin D, Le Bouc Y, Binoux M, Berdal A, Menuelle P, Babajko S (2006). Insulin-like growth factor binding protein (IGFBP-1) involvement in intrauterine growth retardation: study on IGFBP-1 overexpressing transgenic mice. Endocrinology 147: 4730–4737.
Calogero A, Lombari V, De Gregorio G, Porcellini A, Ucci S, Arcella A, Caruso R, Gagliardi FM, Gulino A, Lanzetta G et al. (2004). Inhibition of cell growth by EGR-1 in human primary cultures from malignant glioma. Cancer Cell Int 4: 1.
Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC, Olsen JV, Mann M (2009). Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325: 834–840.
Dellas C, Loskutoff DJ (2005). Historical analysis of PAI-I from its discovery to its potential role in cell motility and disease. Thromb Haemostasis 93: 631–640.
Du X, Kumar J, Ferguson C, Schulz TA, Ong YS, Hong W, Prinz WA, Parton RG, Brown AJ, Yang H (2011). A role for oxysterol- binding protein-related protein 5 in endosomal cholesterol trafficking. J Cell Biol 192: 121–135.
Eferl R, Ricci R, Kenner L, Zenz R, David JP, Rath M, Wagner EF (2003). Liver tumor development: c-Jun antagonizes the proapoptotic activity of p53. Cell 112: 181–192.
Eferl R, Wagner EF (2003). AP-1: A double-edged sword in tumorigenesis. Nat Rev Cancer 3: 859–868.
Ellies LG, Fishman M, Hardison J, Kleeman J, Maglione JE, Manner CK, Cardiff RD, MacLeod CL (2003). Mammary tumor latency is increased in mice lacking the inducible nitric oxide synthase. Int J Cancer 106: 1–7.
Eşrefoğlu M, Akıncı A, Elbe H, Taşlıdere E, Çetin A, Ateş B (2014). Melatonin is effective in reducing stress-induced organ damage in Wistar albino rats. Turk J Biol 38: 493–501.
Finley LW, Haigis MC (2012). Metabolic regulation by SIRT3: implications for tumorigenesis. Trends Mol Med 18: 516–523.
Gao Y, Shen W, Lu B, Zhang Q, Hu Y, Chen Y (2014). Upregulation of hepatic VLDLR via PPARα is required for the triglyceride- lowering effect of fenofibrate. J Lipid Res 55: 1622–1633.
Gay E, Seurin D, Babajko S, Doublier S, Cazillis M, Binoux M (1997). Liver-specific expression of human insulin-like growth factor binding protein-1 in transgenic mice: Repercussions on reproduction, ante- and perinatal mortality and postnatal growth. Endocrinology 138: 2937–2947.
Gholami L, Sadeghnia HR, Darroudi M, Oskuee RK (2014). Evaluation of genotoxicity and cytotoxicity induced by different molecular weights of polyethylenimine/DNA nanoparticles Turk J Biol 38: 380–387.
Green MF, Hirschey MD (2013). SIRT3 weighs heavily in the metabolic balance: a new role for SIRT3 in metabolic syndrome. J Gerontol A Biol Sci Med Sci 68: 105–107.
Heemskerk VH, Daemen MARC, Buurman WA (1999). Insulin- like growth factor-1 (IGF-1) and growth hormone (GH) in immunity and inflammation. Cytokine Growth F R 10: 5–14.
Hirschey MD, Shimazu T, Goetzman E, Jing E, Schwer B, Lombard DB, Grueter CA, Harris C, Biddinger S, Ilkayeva OR et al. (2010). SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. Nature 464: 121–125.
Huang RP, Darland T, Okamura D, Mercola D, Adamson ED (1994). Suppression of V-Sis-dependent transformation by the transcription factor, Egr-1. Oncogene 9: 1367–1377.
Jacobs KM, Pennington JD, Bisht KS, Aykin-Burns N, Kim HS, Mishra M, Sun L, Nguyen P, Ahn BH, Leclerc J et al. (2008). SIRT3 interacts with the daf-16 homolog FOXO3a in the mitochondria, as well as increases FOXO3a dependent gene expression. Int J Biol Sci 4: 291–299.
Jochum W, Passegue E, Wagner EF (2001). AP-1 in mouse development and tumorigenesis. Oncogene 20: 2401–2412.
Kaeberlein M, Jegalian B, McVey M (2002). AGEID: a database of aging genes and interventions. Mech Ageing Dev 123: 1115– 1119.
Kanwar JR, Kanwar RK, Burrow H, Baratchi S (2009). Recent advances on the roles of NO in cancer and chronic inflammatory disorders. Curr Med Chem 16: 2373–2394.
Kim HS, Patel K, Muldoon-Jacobs K, Bisht KS, Aykin-Burns N, Pennington JD, van der Meer R, Nguyen P, Savage J, Owens KM et al. (2010). SIRT3 is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress. Cancer Cell 17: 41–52.
Kisley LR, Barrett BS, Bauer AK, Dwyer-Nield LD, Barthel B, Meyer AM, Thompson DC, Malkinson AM (2002). Genetic ablation of inducible nitric oxide synthase decreases mouse lung tumorigenesis. Cancer Res 62: 6850–6856.
Lee PDK, Giudice LC, Conover CA, Powell DR (1997). Insulin- like growth factor binding protein-1: recent findings and new directions. P Soc Exp Biol Med 216: 319–357.
Lemieux ME, Yang X, Jardine K, He X, Jacobsen K, Staines WA, Harper ME, McBurney MW (2005). The Sirt1 deacetylase modulates the insulin-like growth factor signaling pathway in mammals. Mech Ageing Dev 126: 1097–1105.
Lombard DB, Alt FW, Cheng HL, Bunkenborg J, Streeper RS, Mostoslavsky R, Kim J, Yancopoulos G, Valenzuela D, Murphy A et al. (2007). Mammalian sir2 homolog SIRT3 regulates global mitochondrial lysine acetylation. Mol Cell Biol 27: 8807–8814.
Longo VD, Kennedy BK (2006). Sirtuins in aging and age-related disease. Cell 126: 257–268.
Lu Z, Bourdi M, Li JH, Aponte AM, Chen Y, Lombard DB, Gucek M, Pohl LR, Sack MN (2011). SIRT3-dependent deacetylation exacerbates acetaminophen hepatotoxicity. EMBO Rep 12: 840–846.
Lu ZP, Scott I, Webster BR, Sack MN (2009). The emerging characterization of lysine residue deacetylation on the modulation of mitochondrial function and cardiovascular biology. Circ Res 105: 830–841.
Michishita E, Park JY, Burneskis JM, Barrett JC, Horikawa I (2005). Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Mol Biol Cell 16: 4623–4635.
Mikula M, Gotzmann J, Fischer ANM, Wolschek MF, Thallinger C, Schulte-Hermann R, Beug H, Mikulits W (2003). The proto-oncoprotein c-Fos negatively regulates hepatocellular tumorigenesis. Oncogene 22: 6725–6738.
Musso G, Cassader M, De Michieli F, Saba F, Bo S, Gambino R (2011). Effect of lectin-like oxidized LDL receptor-1 polymorphism on liver disease, glucose homeostasis, and postprandial lipoprotein metabolism in nonalcoholic steatohepatitis. Am J Clin Nutr 94: 1033–1042.
Nam KT, Hahm KB, Oh SY, Yeo M, Han SU, Alm B, Kim YB, Kang JS, Jang DD, Yang KH et al. (2004). The selective cyclooxygenase-2 inhibitor nimesulide prevents Helicobacter pylori-associated gastric cancer development in a mouse model. Clin Cancer Res 10: 8105–8113.
Okawara M, Katsuki H, Kurimoto E, Shibata H, Kume T, Akaike A (2007). Resveratrol protects dopaminergic neurons in midbrain slice culture from multiple insults. Biochem Pharmacol 73: 550–560.
Orucevic A, Bechberger J, Green AM, Shapiro RA, Billiar TR, Lala PK (1999). Nitric-oxide production by murine mammary adenocarcinoma cells promotes tumor-cell invasiveness. Int J Cancer 81: 889–896.
Ozden O, Park SH, Kim HS, Jiang HY, Coleman MC, Spitz DR, Gius D (2011). Acetylation of MnSOD directs enzymatic activity responding to cellular nutrient status or oxidative stress. Aging 3: 102–107.
Park SH, Ozden O, Jiang HY, Cha YI, Pennington JD, Aykin-Burns N, Spitz DR, Gius D, Kim HS (2011). Sirt3, Mitochondrial ROS, Ageing, and Carcinogenesis. Int J Mol Sci 12: 6226–6239.
Peck B, Chen CY, Ho KK, Di Fruscia P, Myatt SS, Coombes RC, Fuchter MJ, Hsiao CD, Lam EWF (2010). SIRT inhibitors induce cell death and p53 acetylation through targeting both SIRT1 and SIRT2. Mol Cancer Ther 9: 844–855.
Reveneau S, Arnould L, Jolimoy G, Hilpert S, Lejeune P, Saint- Giorgio V, Belichard C, Jeannin JF (1999). Nitric oxide synthase in human breast cancer is associated with tumor grade, proliferation rate, and expression of progesterone receptors. Lab Invest 79: 1215–1225.
Rogina B, Helfand SL (2004). Sir2 mediates longevity in the fly through a pathway related to calorie restriction. P Natl Acad Sci USA 101: 15998–16003.
Roninson IB (2005). Seeking favors from nature. Cancer Biol Ther 4: 794–799.
Ronski K, Sanders M, Burleson JA, Moyo V, Benn P, Fang M (2005). Early growth response gene 1 (EGR1) is deleted in estrogen receptor-negative human breast carcinoma. Cancer 104: 925– 930.
Sarbia M, Stahl M, Fink U, Willers R, Seeber S, Gabbert HE (1998). Expression of apoptosis-regulating proteins and outcome of esophageal cancer patients treated by combined therapy modalities. Clin Cancer Res 4: 2991–2997.
Scharf JG, Dombrowski F, Novosyadlyy R, Eisenbach C, Demori I, Kubler B, Braulke T (2004). Insulin-like growth factor (IGF)- binding protein-1 is highly induced during acute carbon tetrachloride liver injury and potentiates the IGF-I-stimulated activation of rat hepatic stellate cells. Endocrinology 145: 3463–3472.
Schwer B, Verdin E (2008). Conserved metabolic regulatory functions of sirtuins. Cell Metab 7: 104–112.
Shaulian E, Karin M (2001). AP-1 in cell proliferation and survival. Oncogene 20: 2390–2400.
Someya S, Yu W, Hallows WC, Xu JZ, Vann JM, Leeuwenburgh C, Tanokura M, Denu JM, Prolla TA (2010). Sirt3 mediates reduction of oxidative damage and prevention of age-related hearing loss under caloric restriction. Cell 143: 802–812.
Tao R, Coleman MC, Pennington JD, Ozden O, Park SH, Jiang H, Kim HS, Flynn CR, Hill S, Hayes McDonald W et al. (2010). Sirt3-mediated deacetylation of evolutionarily conserved lysine 122 regulates MnSOD activity in response to stress. Mol Cell 40: 893–904.
Thiel G, Cibelli G (2002). Regulation of life and death by the zinc finger transcription factor Egr-1. J Cell Physiol 193: 287–292.
Tissenbaum HA, Guarente L (2001). Increased dosage of a sir-2 gene extends lifespan in Caenorhabditis elegans. Nature 410: 227–230. van Gent R, Di Sanza C, van den Broek NJ, Fleskens V, Veenstra A, Stout GJ, Brenkman AB (2014). SIRT1 mediates FOXA2 breakdown by deacetylation in a nutrient-dependent manner. Plos One 9: e98438.
Vericel E, Narce M, Ulmann L, Poisson JP, Lagarde M (1994). Age- related-changes in antioxidant defense-mechanisms and peroxidation in isolated hepatocytes from spontaneously hypertensive and normotensive rats. Mol Cell Biochem 132: 25–29.
Wagayama H, Shiraki K, Sugimoto K, Ito T, Fujikawa K, Yamanaka T, Takase K, Nakano T (2002). High expression of p21(WAF1/ CIP1) is correlated with human hepatocellular carcinoma in patients with hepatitis C virus-associated chronic liver diseases. Hum Pathol 33: 429–434.
Wang JX, Yi Y, Li YW, Cai XY, He HW, Ni XC, Zhou J, Cheng YF, Jin JJ, Fan J et al. (2014). Down-regulation of sirtuin 3 is associated with poor prognosis in hepatocellular carcinoma after resection. BMC Cancer 14: 297.
Winters ZE, Hunt NC, Bradburn MJ, Royds JA, Turley H, Harris AL, Norbury CJ (2001). Subcellular localisation of cyclin B, Cdc2 and p21(WAF1/CIP1) in breast cancer: association with prognosis. Eur J Cancer 37: 2405–2412.
Younossi ZM, Gorreta F, Ong JP, Schlauch K, Giacco LD, Elariny H, Van Meter A, Younoszai A, Goodman Z, Baranova A et al.(2005). Hepatic gene expression in patients with obesity- related non-alcoholic steatohepatitis. Liver Int 25: 760–771.
Yu SS, Cai Y, Ye JT, Pi RB, Chen SR, Liu PQ, Shen XY, Ji Y (2013). Sirtuin 6 protects cardiomyocytes from hypertrophy in vitro via inhibition of NF-KB-dependent transcriptional activity. Brit J Pharmacol 168: 117–128.
Zhang B, Qin L, Zhou CJ, Liu YL, Qian HX, He SB (2013). SIRT3 expression in hepatocellular carcinoma and its impact on proliferation and invasion of hepatoma cells. Asian Pac J Trop Med 6: 649–652.
Zhang CZ, Liu L, Cai M, Pan Y, Fu J, Cao Y, Yun J (2012). Low SIRT3 expression correlates with poor differentiation and unfavorable prognosis in primary hepatocellular carcinoma. PLOS One 7: e51703.
Zhang Y, Wang L (2011). Nuclear receptor small heterodimer partner in apoptosis signaling and liver cancer. Cancers (Basel) 3: 198–212.
Zhang YY, Zhou LM (2012). Sirt3 inhibits hepatocellular carcinoma cell growth through reducing Mdm2-mediated p53 degradation. Biochem Biophys Res Commun 423: 26–31.
Zhu Y, Yan Y, Principe DR, Zou X, Vassilopoulos A, Gius D (2014). SIRT3 and SIRT4 are mitochondrial tumor suppressor proteins that connect mitochondrial metabolism and carcinogenesis. Cancer Metab 2: 15.